Education
About Us
Working with TipRanks
Follow Us
PCI Biotech Holding ASA (GB:0JGL)
LSE:0JGL
0JGL Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr1.22 - kr2.82
Previous CloseN/A
Volume18.85K
Average Volume (3M)912.00
Market Cap
€63.27M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)1.43M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Aug 29, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding37,326,390
10 Day Avg. Volume870
30 Day Avg. Volume912
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
PCI Biotech Holding ASA News
PremiumCompany Announcements
PCI Biotech’s Board Chair to Influence Upcoming AGM
PremiumCompany Announcements
PCI Biotech Announces Annual General Meeting for 2025
PremiumCompany Announcements
PCI Biotech Approves 2024 Annual Report
PremiumCompany Announcements
PCI Biotech Advances Photochemical Technology in Viral Vector Manufacturing
PremiumCompany Announcements
PCI Biotech Announces New CSO and Share Option Grant
PremiumCompany Announcements
PCI Biotech Sets Key Financial Dates for 2024-2025
PremiumCompany Announcements
PCI Biotech Awards Share Options to Executives
PremiumCompany Announcements
PCI Biotech’s Promising Mid-Year Technology Advances0JGL FAQ
What was PCI Biotech Holding ASA’s price range in the past 12 months?
PCI Biotech Holding ASA lowest share price was kr1.22 and its highest was kr2.82 in the past 12 months.
What is PCI Biotech Holding ASA’s market cap?
PCI Biotech Holding ASA’s market cap is €63.27M.
When is PCI Biotech Holding ASA’s upcoming earnings report date?
PCI Biotech Holding ASA’s upcoming earnings report date is Aug 29, 2025 which is in 85 days.
How were PCI Biotech Holding ASA’s earnings last quarter?
PCI Biotech Holding ASA released its earnings results on Feb 27, 2025. The company reported -kr0.242 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.242.
Is PCI Biotech Holding ASA overvalued?
According to Wall Street analysts PCI Biotech Holding ASA’s price is currently Overvalued.
Does PCI Biotech Holding ASA pay dividends?
PCI Biotech Holding ASA does not currently pay dividends.
What is PCI Biotech Holding ASA’s EPS estimate?
PCI Biotech Holding ASA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PCI Biotech Holding ASA have?
PCI Biotech Holding ASA has 37,326,390 shares outstanding.
What happened to PCI Biotech Holding ASA’s price movement after its last earnings report?
PCI Biotech Holding ASA reported an EPS of -kr0.242 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PCI Biotech Holding ASA?
Currently, no hedge funds are holding shares in GB:0JGL
Company Description
PCI Biotech Holding ASA
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.